A TTUHSC research team led by Srinivas Nandana, Ph.D., (center) and Manisha Tripathi, Ph.D., (left) recently completed a study focused on uncovering the molecular and signaling mechanisms that drive ...
This figure shows the structure of PTGES3. The research team made the association after creating a fluorescent tag that tracks androgen receptor levels in real time. The androgen receptor is a hormone ...
A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...
Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
Prostate cancer hijacks the normal prostate's growth regulation program to release the brakes and grow freely, according to Weill Cornell Medicine researchers. The discovery, published Dec. 13 in ...
Trial in progress (XALute): Phase 3 study of xaluritamig vs investigator’s choice of cabazitaxel or second androgen receptor directed therapy (ARDT) in post-taxane metastatic castration-resistant ...
A phase 1b, open-label, multicenter study of xaluritamig in patients with biochemical recurrence of prostate cancer after definitive therapy. Evaluation of circulating kidney injury marker-1 (KIM-1) ...
A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results